India, April 15 -- Clearmind Medicine Inc. (CMND) announced that its independent Data and Safety Monitoring Board has issued a positive recommendation to continue the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder.
Alcohol Use Disorder (AUD) is a widespread condition that affects millions globally, often with limited effective treatment options. CMND-100 is Clearmind's proprietary, non-hallucinogenic MEAI-based oral drug candidate designed to address moderate to severe AUD.
The DSMB recommendation followed the successful completion of the third patient cohort, with top-line safety data showing that CMND-100 was well tolerated and no serious adverse events were reported. These findings reinforce the fa...